Pet Home Diagnostic Tests Market Report: Market Size & Forecast 2026

The global pet at-home diagnostic tests market encompasses rapid immunoassay kits and lateral flow diagnostic products designed for use by pet owners outside veterinary clinic settings. The market was valued at approximately $80 million in 2024 and is forecast to reach roughly $111 million by 2030 at a 5.8% compound annual growth rate, with some projections extending toward $135-138 million by the early 2030s. This segment represents a specialized and growing subset of the broader veterinary diagnostics industry, which encompasses in-clinic testing, reference laboratory services, and imaging technologies across companion and production animal categories.

• •Market estimated at $80.14 million in 2024, with multiple projections converging around $110-138 million by 2030-2035 at a 5.8% CAGR
• •Product scope includes rapid immunoassay test kits for heartworm, parvovirus, feline leukemia, Lyme disease, and other common companion animal conditions
• •Forms a distinct niche within the broader pet care and veterinary diagnostics ecosystem

Rising global pet ownership rates, particularly in developed and emerging economies, have steadily expanded the addressable consumer base for at-home diagnostic products. The growing humanization of pets, where owners increasingly regard companion animals as family members, has significantly raised willingness to invest in preventive healthcare and early-detection products. Additionally, rising veterinary care costs, longer wait times for appointments, and the desire for immediate health monitoring without clinic visits have accelerated consumer adoption of at-home testing solutions.

• •Increasing companion animal populations and pet ownership rates worldwide, especially in urbanizing markets
• •Pet humanization trend driving demand for preventive healthcare, wellness monitoring, and early disease detection products
• •Rising veterinary service costs and convenience preferences pushing pet owners toward at-home and over-the-counter diagnostic alternatives

The market is segmented by product type, including rapid immunoassay test kits, lateral flow assays, and other point-of-care diagnostic platforms adapted for companion animal use. Geographically, North America commands the largest market share, supported by high pet ownership rates, advanced veterinary infrastructure, and strong consumer awareness of pet health products. The U.S. veterinary point-of-care diagnostics market alone was valued at approximately $1.04 billion in 2024 and is projected to expand to $1.78 billion by 2030, reflecting robust regional demand dynamics. Europe and Asia-Pacific represent growing markets, with Asia-Pacific expected to register the fastest growth rates as middle-class pet adoption accelerates in emerging economies.

• •Product segments include lateral flow immunoassay test kits, rapid antigen/antibody tests, and other point-of-care diagnostic platforms for companion animals
• •North America leads the market; the U.S. veterinary point-of-care diagnostics segment at $1.04 billion (2024) is projected to approach $1.78 billion by 2030
• •Asia-Pacific anticipated to be the fastest-growing regional market driven by rising pet adoption and increasing disposable incomes

Who are the notable companies in the industry?

The pet at-home diagnostic tests market remains relatively fragmented, with a competitive spectrum spanning large diversified veterinary diagnostic manufacturers and smaller specialty producers focused specifically on companion animal rapid testing. The industry structure includes integrated producers with broad portfolios spanning both animal and human diagnostics, alongside pure-play veterinary diagnostics firms concentrated on rapid and point-of-care testing technologies. Production relies primarily on immunoassay, lateral flow chromatography, and point-of-care diagnostic processes, many adapted from established human medical testing platforms and applied to veterinary use cases. Manufacturing and research-and-development capacity is concentrated primarily in North America and Europe, with growing production and sourcing activity in Asia-Pacific as regional demand expands.

• •Moderate market fragmentation with a mix of large diversified diagnostics manufacturers and smaller specialty producers focused on veterinary rapid testing
• •Core technology platforms centered on lateral flow immunoassay, rapid antigen detection, and point-of-care chromatography processes adapted from human diagnostic applications
• •Manufacturing and R&D capacity concentrated in North America and Europe, with increasing production activity in Asia-Pacific to serve growing regional demand

What are the recent trends and outlook?

The pet rapid tests segment is projected to grow at a notably faster rate of approximately 14.4% annually through 2033, outpacing the broader at-home diagnostics market and signaling strong future potential within the overall veterinary diagnostics space. E-commerce and direct-to-consumer distribution channels are gaining prominence as primary routes for purchasing at-home test kits, reducing traditional reliance on veterinary clinic-based retail. As diagnostic accuracy improves, product portfolios expand to cover a wider range of companion animal conditions, and consumer education increases, at-home testing is expected to capture an increasingly significant share of the overall veterinary diagnostics market over the forecast horizon.

• •Pet rapid tests segment projected at 14.4% CAGR through 2033, substantially outpacing the broader at-home diagnostics market's 5.8% growth rate
• •E-commerce platforms and direct-to-consumer sales channels gaining traction as primary distribution routes, expanding market accessibility beyond traditional retail and clinic channels
• •Expanding product portfolios, improved test accuracy, and growing consumer awareness expected to drive greater adoption relative to traditional in-clinic diagnostic services